Companies: 10,795·Total market cap: $144.5T
Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc.

ORKANASDAQHealthcare● Active
$65.61
+$1.55(+2.42%)
Market Cap$2.5B
P/E Ratio
52W High$91
52W Low$10.77
SEC Filings

Oruka Therapeutics, Inc. (ORKA) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0000907654 · ORKA · NASDAQ · as of Jun 9, 2026

Filing snapshot

1,000+
Total Filings
8-K
Latest Form
2026-06-04
Most Recent
1997
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0000907654 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-12
Fiscal Year End
Mar 12, 2026
Accession No.
0001213900-26-026929
Primary Document
ea0273300-10k_oruka.htm
Source: data.sec.gov · CIK 0000907654 · Accession 0001213900-26-026929

Latest Key Filings

10-QQuarterly Report
QUARTERLY REPORT
2026-05-13
8-KCurrent Report
CURRENT REPORT
2026-06-04Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
CURRENT REPORT
2026-06-04
View
8-KCurrent Report
CURRENT REPORT
2026-06-01
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
10-QQuarterly Report
QUARTERLY REPORT
2026-05-13
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-05-04
View
8-KCurrent Report
CURRENT REPORT
2026-04-30
View
424B5424B5
PROSPECTUS SUPPLEMENT
2026-04-29
View
424B5424B5
PRELIMINARY PROSPECTUS SUPPLEMENT
2026-04-27
View
424B5424B5
PRELIMINARY PROSPECTUS SUPPLEMENT
2026-04-27
View
8-KCurrent Report
CURRENT REPORT
2026-04-27
View
424B7424B7
PROSPECTUS SUPPLEMENT
2026-04-21
View
ARSARS
ANNUAL REPORT
2026-04-17
View
DEFA14AProxy Statement (Additional)
PROXY STATEMENT
2026-04-17
View
DEF 14AProxy Statement
PROXY STATEMENT
2026-04-17
View
EFFECTEFFECT
EFFECT
2026-04-10
View
Showing 1–15 of 750 filingsForm 4 / 144 hidden· 1000 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0000907654  |  Exchange: NASDAQ · Healthcare

Oruka Therapeutics, Inc. (NASDAQ: ORKA) has submitted 1,000+ documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 1997. As a Healthcare sector company with CIK 0000907654, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Oruka Therapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Oruka Therapeutics, Inc. 10-K was filed on 2026-03-12 for fiscal year ending 2026. Historical ORKA 10-K annual reports are available from 2009 through 2026.

Investors researching Oruka Therapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09

Frequently Asked Questions

ORKA SEC Filings · 8 questions

Oruka Therapeutics, Inc. (ORKA) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 1,000+ filings and access original documents at no cost. Oruka Therapeutics, Inc.'s CIK is 0000907654.

ORKA SEC filingsOruka Therapeutics, Inc. SEC documentsfind ORKA 10-K